Non-Small-Cell Lung Cancer | Current Treatment | US | 2016
Genomic aberration status, histology, performance status, and stage of disease are key factors that influence the treatment of non-small-cell lung cancer (NSCLC). The characterization of biomarker-defined patient populations and the FDA’s approval of several targeted therapies in 2015 have positioned NSCLC at the forefront of personalized medicine in oncology and resulted in an evolving treatment landscape for the disease. This analysis provides insight on current use of approved therapies for NSCLC in the United States and on oncologists’ perception of these therapies.
Related Market Assessment Reports
Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
Report
Hepatocellular Carcinoma – Geographic Focus: China – Hepatocellular Carcinoma – China In-Depth (China)
The hepatocellular carcinoma therapy market in China is poised to experience significant growth, driven by an aging population and the high prevalence of hepatitis B and C infection. Angiogenesis…
Report
Atrial Fibrillation – Current Treatment – Treatment Algorithms: Claims Data Analysis – Atrial Fibrillation (US)
Atrial fibrillation (AF) is a common arrhythmia characterized by irregular, often rapid heartbeats in the atria, increasing the risk of stroke and cardiovascular complications. Management typically…
